It's close to the heart.
(Reading time: 4 - 7 minutes)
Biotech. Every year in Germany alone, more than 200,000 people suffer a heart attack. Fortunately, fewer and fewer die of it. However, many survivors then develop heart failure, which is often fatal. The biotech company Cardior wants to put an end to this complication - with an elegant process that impressively demonstrates how much potential biotechnology has.